spacer
home > ict > autumn 2016 > get involved
PUBLICATIONS
International Clinical Trials

Get Involved

Several studies have shown that applications of mHealth in healthcare settings have improved medication and procedural compliance (1); however, little research has been conducted on the effect of mHealth on clinical trial adherence and patient retention.

Clinical Ink piloted an mHealth sub-study with 30 subjects using a hybrid bring-your-own-device (BYOD)/provisioned device model, and results have indicated a low 6% subject dropout rate; a high average study procedure compliance of 84%; and high data quality. These data suggest that mHealth has an impact on reducing subject dropout rates, potentially improving protocol adherence and changing patient behaviour.

Research has shown that mHealth significantly enhances medication adherence, reduces non-adherence related adverse effects, and is accepted in healthcare in various geographic settings and among diverse demographic groups (1). Studies have also demonstrated that mHealth improves both recruitment and enrolment in clinical trials (2,3). Considering this with data showing nearly 43% of the global population and 68% of US adults owning a smartphone in 2015, advancing a BYOD approach (such as apps on a patient’s smartphone) in mHealth is inevitable (4,5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Kyle Hogan is eClinical Solutions Director with Clinical Ink, and is responsible for the strategic alignment of the company’s native mobile application for clinical trials. Kyle has delivered technical solutions for complex business challenges since the 1990s, and has more than nine years of experience in clinical trials.
spacer
Kyle Hogan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

Outsourcing in Clinical Trials Europe

26-27 October 2020, Paris, France

Arena International are delighted to announce the return of Outsourcing in Clinical Trials Europe. Part of our global series of events, this flagship show will attract the leading clinical professionals from across Europe. The 10th Annual event will be hosted in Paris.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement